PMLiVE30m
Amgen’s Blincyto recommended by NICE for new adult leukaemia indication
Amgen’s Blincyto (blinatumomab) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat ...
PMLiVE31m
AstraZeneca’s camizestrant shows promise in phase 3 breast cancer study
The phase 3 SERENA-6 study randomised patients with HR-positive, HER2-negative advanced breast cancer whose tumours had an ...
PMLiVE34m
J&J’s shares positive results for subcutaneous Tremfya in phase 3 ulcerative colitis trial
Johnson & Johnson (J&J) has shared positive results from a late-stage study evaluating a subcutaneous (SC) version of Tremfya ...
PMLiVE36m
NHS England appoints Sir James Mackey as CEO
NHS England has announced that it has appointed Sir James Mackey as its new chief executive officer (CEO), following Amanda ...